Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Signal Transduction
Stem Cells
Product Type
All Products
New Products
Small Molecules
Peptides
Antibodies
Jena Bioscience
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular Disease
Endocrinology
Immunology
Metabolic Disease
Neurological Disease
Pain & Inflammation
Respiratory Disease
Home »
Pharmacology » Enzyme-Linked Receptors » Receptor Serine/Threonine Kinases (RSTKs) » TGF-β Receptors » SB 525334
SB 525334Cat No. 3211 |
Price and Availability |
|
Chemical Name: 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-im idazol-4-yl]quinoxaline |
|
Biological Activity
Selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC50 = 14.3 nM). Inhibits TGF-β1-induced smad2/3 nuclear localisation and TGF-β1-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis.Licensing Information
Sold with the permission of GlaxoSmithKlineTechnical Data
M.Wt:343.42
Formula:C21H21N5
Solubility:Soluble to 100 mM in DMSO and to 100 mM in 1eq. HCl
Purity: >98 %
Storage:Store at -20°C
CAS No:[356559-20-1]
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis and MSDS.
Resources
Certificate of Analysis / MSDS
Certificate of Analysis: View current batch
For specific/earlier batch please select:
Material Safety Data Sheet: View current batch
For specific/earlier batch please select:
References
Grygielko et al (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-b type I receptor kinase in puromycin-induced nephritis. J.Pharmacol.Exp.Ther. 313 943. Higashiyama et al (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp.Mol.Pathol. 83 39. Laping et al (2007) Tumor-specific efficacy of transforming growth factor-bRI inhibition in eker rats. Clin.Cancer Res. 13 3087.If you know of a useful citation for this product please let us know.
Keywords: SB 525334, Selective, inhibitors, TGF-βRI, TGF-β, TGF-betaRI, TGFbRI, TGFbR1, tgf-b1Transforming, Growth, Factor, Beta, Receptors, TGF-β, TGF-beta, Receptor, Serine/Threonine, Kinases, RSTKs, SB525334, GlaxoSmithKline







